scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.YMGME.2009.02.008 |
P698 | PubMed publication ID | 19307142 |
P50 | author | Sharon Byers | Q58055535 |
P2093 | author name string | Donald S Anson | |
Rachel Koldej | |||
Jelena Lalic | |||
Miriam Rothe | |||
P2860 | cites work | Correction of mucopolysaccharidosis type IIIb fibroblasts by lentiviral vector-mediated gene transfer | Q24534147 |
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding | Q25938984 | ||
Gene transfer to human joints: progress toward a gene therapy of arthritis | Q33853972 | ||
Arylsulfatase B-deficient mucopolysaccharidosis in rats | Q33893772 | ||
Prevalence of lysosomal storage disorders | Q34489300 | ||
Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA. | Q35613015 | ||
Gene therapy for the treatment of musculoskeletal diseases. | Q36236529 | ||
Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects | Q36477567 | ||
NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint | Q36803920 | ||
Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. | Q37363292 | ||
Targeted disruption of the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI | Q37396626 | ||
Mucopolysaccharidosis in a Cat with Arylsulfatase B Deficiency: A Model of Maroteaux-Lamy Syndrome | Q39832785 | ||
Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large-scale production | Q40396420 | ||
An improved beta-galactosidase reporter gene | Q40596039 | ||
Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy | Q42099566 | ||
Helper plasmids for production of HIV-1-derived vectors | Q42822878 | ||
Rational development of a HIV‐1 gene therapy vector | Q42835119 | ||
Human N-acetylgalactosamine-4-sulphate sulphatase. Purification, monoclonal antibody production and native and subunit Mr values | Q42857331 | ||
In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors | Q44016335 | ||
Lentiviral-mediated gene delivery to synovium: potent intra-articular expression with amplification by inflammation | Q44869190 | ||
Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). | Q44883627 | ||
Transduction of passaged human articular chondrocytes with adenoviral, retroviral, and lentiviral vectors and the effects of enhanced expression of SOX9. | Q44912353 | ||
Feline immunodeficiency virus vectors for efficient transduction of primary human synoviocytes: application to an original model of rheumatoid arthritis | Q45623974 | ||
Recombinant caprine 3H-[N-acetylglucosamine-6-sulfatase] and human 3H-[N-acetylgalactosamine-4-sulfatase]: plasma clearance, tissue distribution, and cellular uptake in the rat. | Q48200022 | ||
Long-term gene expression using the lentiviral vector in rat chondrocytes. | Q50752002 | ||
In vivo gene delivery to synovium by lentiviral vectors. | Q53974167 | ||
Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) | Q63197223 | ||
Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4 | Q64380123 | ||
Clinical vignette. Mucopolysaccharidosis VI in a miniature pinscher | Q70892008 | ||
Feline mucopolysaccharidosis type VI. Characterization of recombinant N-acetylgalactosamine 4-sulfatase and identification of a mutation causing the disease | Q71762921 | ||
Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI | Q73843946 | ||
Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses | Q74509531 | ||
Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI | Q80419661 | ||
Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval | Q82890246 | ||
P433 | issue | 2 | |
P304 | page(s) | 102-108 | |
P577 | publication date | 2009-02-27 | |
P1433 | published in | Molecular Genetics and Metabolism | Q6895949 |
P1476 | title | Lentiviral-mediated correction of MPS VI cells and gene transfer to joint tissues | |
P478 | volume | 97 |
Q45874835 | Gene Delivery to Joints by Intra-articular Injection. |
Q37994717 | Gene therapy approaches for lysosomal storage disorders, a good model for the treatment of mendelian diseases |
Q37816955 | Getting arthritis gene therapy into the clinic |
Q35367599 | Glycosaminoglycan storage disorders: a review |
Q35173582 | IL-1RA gene-transfected bone marrow-derived mesenchymal stem cells in APA microcapsules could alleviate rheumatoid arthritis |
Q30537079 | Optimization of scAAVIL-1ra In Vitro and In Vivo to Deliver High Levels of Therapeutic Protein for Treatment of Osteoarthritis |
Q33713231 | Orthopedic gene therapy in 2008. |
Q40608919 | Orthopedic gene therapy--lost in translation? |
Q45858781 | Reversal of established bone pathology in MPS VII mice following lentiviral-mediated gene therapy |
Q43855295 | Rhodamine B and 2-acetamido-1,3,6-tri-O-acetyl-4-deoxy-4-fluoro-D-glucopyranose (F-GlcNAc) inhibit chondroitin/dermatan and keratan sulphate synthesis by different mechanisms in bovine chondrocytes |
Q34545883 | Therapies of mucopolysaccharidosis IVA (Morquio A syndrome). |
Search more.